Cumberland Pharmaceuticals Shares Updated Trial Results For Duchenne Muscular Dystrophy Heart Disease Treatment Showing A 30% Reduction In MYL3 And 50% Reduction In MYOD1 With A Favorable Safety Profile Over A 36-Month Period